NO940778L - Mutert vekstfaktorreseptor som et legemiddel og dets anvendelse til å behandle kreft - Google Patents

Mutert vekstfaktorreseptor som et legemiddel og dets anvendelse til å behandle kreft

Info

Publication number
NO940778L
NO940778L NO940778A NO940778A NO940778L NO 940778 L NO940778 L NO 940778L NO 940778 A NO940778 A NO 940778A NO 940778 A NO940778 A NO 940778A NO 940778 L NO940778 L NO 940778L
Authority
NO
Norway
Prior art keywords
growth factor
treatment
cancer
drug
receptor
Prior art date
Application number
NO940778A
Other languages
English (en)
Norwegian (no)
Other versions
NO940778D0 (no
Inventor
Norbert Redemann
Axel Ulrich
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of NO940778D0 publication Critical patent/NO940778D0/no
Publication of NO940778L publication Critical patent/NO940778L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO940778A 1991-09-05 1994-03-04 Mutert vekstfaktorreseptor som et legemiddel og dets anvendelse til å behandle kreft NO940778L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19914129533 DE4129533A1 (de) 1991-09-05 1991-09-05 Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
PCT/EP1992/002058 WO1993005148A1 (de) 1991-09-05 1992-09-07 Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs

Publications (2)

Publication Number Publication Date
NO940778D0 NO940778D0 (no) 1994-03-04
NO940778L true NO940778L (no) 1994-05-04

Family

ID=6439926

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940778A NO940778L (no) 1991-09-05 1994-03-04 Mutert vekstfaktorreseptor som et legemiddel og dets anvendelse til å behandle kreft

Country Status (12)

Country Link
EP (1) EP0667899A1 (pt)
JP (1) JPH07502884A (pt)
CN (1) CN1071586A (pt)
AU (1) AU669857B2 (pt)
CA (1) CA2117073A1 (pt)
DE (1) DE4129533A1 (pt)
FI (1) FI941053A (pt)
MX (1) MX9205084A (pt)
NO (1) NO940778L (pt)
NZ (1) NZ244239A (pt)
PT (1) PT100844A (pt)
WO (1) WO1993005148A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465623B2 (en) 1995-05-02 2002-10-15 Garvan Institute Of Medical Research GDU, a novel signalling protein
AUPN274295A0 (en) * 1995-05-02 1995-05-25 Garvan Institute Of Medical Research GDU, a novel signalling protein
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
ES2741574T3 (es) 2004-03-31 2020-02-11 Massachusetts Gen Hospital Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721983A1 (en) * 1988-01-22 1996-07-17 ZymoGenetics, Inc. Methods of producing biologically active peptide dimers
WO1990008160A1 (en) * 1989-01-20 1990-07-26 Imperial Cancer Research Technology Ltd. Growth factor receptor-like peptides without tyrosine-kinase activity
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
WO1990014357A1 (en) * 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
DE69025946T2 (de) * 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma

Also Published As

Publication number Publication date
MX9205084A (es) 1993-05-01
AU669857B2 (en) 1996-06-27
FI941053A0 (fi) 1994-03-04
FI941053A (fi) 1994-04-08
AU2518592A (en) 1993-04-05
PT100844A (pt) 1994-05-31
WO1993005148A1 (de) 1993-03-18
DE4129533A1 (de) 1993-03-11
JPH07502884A (ja) 1995-03-30
EP0667899A1 (de) 1995-08-23
CN1071586A (zh) 1993-05-05
CA2117073A1 (en) 1993-03-18
NO940778D0 (no) 1994-03-04
NZ244239A (en) 1995-07-26

Similar Documents

Publication Publication Date Title
WO1995024190A3 (en) Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
ATE331514T1 (de) Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
JO2319B1 (en) Andazole compounds and pharmaceutical ingredients to inhibit the action of protein enzymes and methods of use
NO20021166L (no) Tyrosinkinase-inhibitorer
MXPA06001193A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular.
MY128370A (en) Pyrrolotriazane inhibitors of kinases
GB9323165D0 (en) Compounds
HUP0002084A2 (hu) Kinolin- és kinoxalinszármazékok, melyek gátolják a vérlemezke-eredetű növekedési faktort és/vagy a p56lck tirozin-kinázokat és a vegyületeket tartalmazó gyógyászati készítmények
DE69631423D1 (de) Chinolone und deren therapeutische verwendung
AU2911489A (en) Quinoline derivatives as antagonists of leukotriene d4
NO20002121L (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
DK0909315T3 (da) CCK-2, en receptortyrosinkinase
NO20053486L (no) 2-(1H-indazol-6-ylamin)-benzamidforbindelser som proteinkinase inhibitorer anvendelig for behanding av oftalmiske sykdommer
GB9806739D0 (en) Cyclin dependent kinase inhibitors
NO940778L (no) Mutert vekstfaktorreseptor som et legemiddel og dets anvendelse til å behandle kreft
Kleinberger-Doron et al. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase
IL129787A0 (en) Isolated tumor necrosis factor receptor releasing enzyme compositions comprising the enzyme and methods of the use thereof
TR199700956T1 (xx) Indazolkarboksamidler.
Gangopadhyay et al. Carcinoembryonic antigen induces signal transduction in Kupffer cells
ATE143808T1 (de) Proteintyrosinphosphatase alpha - inhibitoren zur tumorbehandlung
Burns et al. Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase: modulation of non-catalytic binding sites
Manzow et al. Evidence against a role of general protein kinase C downregulation in skin tumor promotion
HUT54494A (en) Process for producing pharmaceutical compositions comprising buspirone and its salts
Liu et al. Partial agonist effects of BW A868C, a selective DP receptor antagonist, on Cl− secretion in dog tracheal epithelium